(IN BRIEF) The Institute of Cancer Research, London, has published two major studies demonstrating how pairing a cancer-killing reovirus with targeted therapies such as talazoparib and palbociclib can greatly strengthen immune activity and tumour destruction. By disrupting cancer cell defences … Read the full press release →
Posted in Business, Education, Financial, Healthcare, Industrial, Investment, Management, Marketing, News, Science, Technology, United Kingdom
Tagged Cancer Research UK, immune activation, immune checkpoint inhibitors, Joan Kyula-Currie, Kevin Harrington, London, Nature Communications, oncolytic virus, Oncolytics Biotech, Palbociclib, PARP-1, personalised cancer therapies, reovirus, RIG-I, Royal Marsden, talazoparib, The Institute of Cancer Research, tumour stress response, Victoria Roulstone, virotherapy